Nuo Therapeutics Wins 2014 MarCom Platinum Award

GAITHERSBURG, Md., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that it, along with its marketing partner BLDG Health, was presented with the 2014 Platinum MarCom Award by the Association of Marketing and Communication Professionals (AMCP) for its sales education modules designed to support the recently launched Aurix System™. In addition, Nuo and BLDG Health were awarded with an Honorable Mention for the Aurix System™ microsite in the 2014 competition.

The annual international awards competition recognizes exceptional creative achievement by marketing and communication professionals, and receives entries from across the globe. MarCom is one of the largest awards programs in the world, with more than 6,000 entries this year from 34 countries, including all 50 U.S. states and all provinces and territories of Canada.

Andrew Cohen, Vice President of Marketing at Nuo Therapeutics, commented, "Earning a MarCom Award is a great accomplishment, as it truly reflects thought, dedication, and effort that is committed in bringing communication programs to life. MarCom sets the standard in the field and it is particularly rewarding for our education modules to be recognized along with the best across many different industries."

Dean Tozer, Chief Commercial Officer, added, "This award underscores the passion we have for developing tools to support healthcare providers and help them understand the value of the Aurix System™ and its compelling clinical and economic value. For Nuo Therapeutics and our marketing partner BLDG, winning a MarCom Award is a fitting acknowledgment of the quality of the effort we have committed to transform the Company and Product to our market space."

About BLDG Health

BLDG Health is a healthcare marketing agency based in San Diego, CA. For additional information please visit:

About Nuo Therapeutics

Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies for wound care. The Company's flagship product, Aurix™ is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. For additional information please visit or

Safe Harbor Statement -- Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Nuo Therapeutics actual results may differ materially due to a number of factors, many of which are beyond Nuo Therapeutics' ability to predict or control. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Nuo Therapeutics, Inc. Nuo Therapeutics operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Nuo Therapeutics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2013, the most recent Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2014, and other subsequent public filings. These filings are available at

CONTACT: Nuo Therapeutics, Inc. Martin Rosendale, CEO Steven Shallcross, EVP/CFO 240-499-2680 Investors / Media: The Ruth Group Lee Roth / Kirsten Thomas 646-536-7012 / 7014 /

Source:Nuo Therapeutics, Inc.